I'll research Bristol-Myers Squibb (BMY) before writing the preview. Let me gather recent earnings, filings, news, and price data.Let me read the most recent Q1 2026 earnings materials and check for recent guidance/pipeline news.Let me pull the year-ago Q2 2025 release for comparison and the Q1 2026 call transcript for narrative/catalysts.Let me quickly scan the Q1 2026 earnings call transcript for forward catalysts and key management commentary.Let me quickly check for consensus estimates and any recent analyst actions.I have enough to write a comprehensive preview. Let me compile the key figures and draft it.Now I have everything I need. Here's the preview:
BMY heads into Q2 as a "show-me" story that has been quietly working. The stock is up ~19% year-to-date and trades near a 52-week high (~$63.66 vs. a $42.52–$63.44 range), yet still sits at only ~10x forward earnings with a ~4% dividend yield. The debate is unchanged: bears fixate on the looming patent cliff (Eliquis, Opdivo, the collapse of Revlimid), while bulls point to a re-accelerating "Growth Portfolio," a data-rich second half of 2026, cheap valuation, and a durable dividend. This print is less about the quarter itself and more about whether management sustains the "trending toward the upper end of guidance" narrative into the catalyst-heavy back half.
| Metric | Q2 2026 Consensus | Q2 2025 Actual | Notes |
|---|---|---|---|
| Revenue | ~$11.67–11.74B | $12.27B | Implies ~-4 to -5% YoY — legacy erosion + tough comp |
| Non-GAAP EPS | ~$1.59–1.61 | $1.46* | Prior-year included a $(0.57)* BioNTech IPRD charge, so the underlying EPS comp is much tougher than it looks |
| FY26 revenue guide | $46.0–47.5B | — | Reaffirmed in Q1; management says trending to upper end |
| FY26 non-GAAP EPS guide | $6.05–$6.35 | — | Also trending to upper end |
BMY has a strong recent beat track record (it topped Q1 2026 at $1.58 vs. ~$1.42 est., and has beaten each of the last four quarters), so a modest headline beat is largely expected. The more important question is the quality and durability of the beat.
BMY's story is a race between two portfolios. In Q1 2026 this played out clearly:
Growth Portfolio (+9% ex-FX to $6.2B) — the reason to own the stock: - Camzyos (~$314M, +94% ex-FX) — the marquee cardiology growth driver, approaching 25,000 U.S. patients. Watch for early impact from Cytokinetics' aficamten competition; management insists differentiation is minimal and REMS familiarity favors them. - Breyanzi (+53%), Reblozyl (+15%), Opdualag (+15%) — durable double-digit growers. - Cobenfy (~$56M) — the schizophrenia launch remains the single most-scrutinized number. The ramp has been described as "steady" but slower than bulls hoped; any acceleration (or lack thereof) will move sentiment. - Opdivo/Qvantig — Opdivo fell 8% ex-FX in Q1 on a U.S. wholesaler inventory drawdown; management flagged it may or may not normalize. Watch whether the subcutaneous Qvantig conversion (>10% of IV converted, targeting 30–40% in two years) offsets the base erosion.
Legacy Portfolio (-8% ex-FX) — the anchor: - Revlimid collapsed ~63% YoY in Q1 as generics ramp — the biggest single drag. - Eliquis is the swing factor. It grew 13% ex-FX in Q1, but that included a wholesaler inventory build tied to the January U.S. price cut that management explicitly said would reverse in Q2. Don't be surprised by a soft sequential Eliquis print — the full-year guide is still +10–15%. Also note the new cash-pay channels (Cost Plus Drugs at $345/30-day; Eliquis 360 direct-to-patient).
Management has framed late 2026 as an inflection for the long-term growth profile. Any updated timing/confidence commentary on these will matter more than the quarter: - Milvexian (Librexia) — Factor XIa inhibitor in atrial fibrillation and secondary stroke prevention; Phase 3 readouts expected year-end. AFib tests non-inferiority vs. apixaban plus superiority on bleeding. This is the biggest single value driver — "blockbuster potential" per management. - Cobenfy in Alzheimer's disease psychosis (ADEPT program) — multiple readouts expected by year-end (needs ~2 positive studies). - Admilparant (LPA1, first-in-class) in IPF — Phase 3 readout in 2H; PPF just after. - Iberdomide (CELMoD) — PDUFA August 17, 2026 for r/r multiple myeloma (potential first approved CELMoD); Phase 3 PFS data expected late year. Mezigdomide's SUCCESSOR-2 was positive and will feature at ASCO.
Given this line-up, expect analysts to press management on de-risking these trials and on business-development appetite — management reiterated it is "size agnostic," doesn't "need to chase deals," but has firepower for both near-term-growth and early/mid-stage bolt-ons.
Also note the recently expanded Nvidia AI partnership (announced July 20) to accelerate drug discovery — a soft-positive narrative item, unlikely to move numbers.
With the stock near highs and sentiment "balanced" (roughly a "Moderate Buy" consensus, avg. target ~$62–63, i.e. limited implied upside), the bar for a positive surprise has risen. A clean beat-and-raise likely needs to be paired with confident pipeline commentary to push the stock through its 52-week high; anything ambiguous on Cobenfy or Eliquis could trigger profit-taking after the strong YTD run.
Note: BMY's "non-GAAP EPS" includes acquired-IPRD/licensing charges, which are lumpy quarter to quarter (e.g., the $(0.57) BioNTech hit last Q2). When comparing YoY EPS, strip these out to gauge underlying operating performance.
This is an informational earnings preview, not investment advice.